Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions

Fundamentals of Biostatistics.

Richard G. Cornell, Bernard Rosner · Journal of the American Statistical Association · 1987 · 1.6K citations

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

Alberto Gabizón, Raphael Catane, Beatrice Uziely et al. · PubMed · 1994 · 1.4K citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

Franco M. Muggia, John D. Hainsworth, Susan Jeffers et al. · Journal of Clinical Oncology · 1997 · 657 citations

Medicine, Oncology, Pharmacology +17

Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy

Alberto Gabizón · Cancer Investigation · 2001 · 566 citations

Pharmacy, Oncology, Pharmacology +17

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

Beatrice Uziely, Susan Jeffers, Rut Isacson et al. · Journal of Clinical Oncology · 1995 · 478 citations

Medicine, Oncology, Pharmacology +15